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Abstract
High-confidence prediction of complex traits such as disease risk or drug response is an ultimate goal
of personalized medicine. Although genome-wide association studies have discovered thousands of well-
replicated polymorphisms associated with a broad spectrum of complex traits, the combined predictive
power of these associations for any given trait is generally too low to be of clinical relevance. We propose a
novel systems approach to complex trait prediction, which leverages and integrates similarity in genetic,
transcriptomic or other omics-level data. We translate the omic similarity into phenotypic similarity
using a method called Kriging, commonly used in geostatistics and machine learning. Our method
called OmicKriging emphasizes the use of a wide variety of systems-level data, such as those increasingly
made available by comprehensive surveys of the genome, transcriptome and epigenome, for complex trait
prediction. Furthermore, our OmicKriging framework allows easy integration of prior information on
the function of subsets of omics-level data from heterogeneous sources without the sometimes heavy
computational burden of Bayesian approaches. Using seven disease datasets from the Wellcome Trust
Case Control Consortium (WTCCC), we show that OmicKriging allows simple integration of sparse and
highly polygenic components yielding comparable performance at a fraction of the computing time of
a recently published Bayesian sparse linear mixed model method. Using a cellular growth phenotype,
we show that integrating mRNA and microRNA expression data substantially increases performance
over either dataset alone. We also integrate genotype and expression data to predict change in LDL
cholesterol levels after statin treatment and show that OmicKriging performs better than the polygenic
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2score method. We provide an R package to implement OmicKriging
(http://www.scandb.org/newinterface/tools/OmicKriging.html).
Author Summary
Recent advances in the development of the technology to query the structure and function of DNA,
RNA, protein and other biomolecules set the stage for the use of genomic information for individualized
risk prediction and optimized clinical care. In this manuscript, we propose a novel systems approach to
complex trait prediction. We translate the similarity in DNA, RNA levels or other biomolecular profiles
into phenotypic similarity using a method called Kriging, commonly used in geostatistics and machine
learning. Our method called OmicKriging emphasizes the integrative use of a wide variety of systems-level
data, such as those increasingly made available by comprehensive surveys of the genome, transcriptome
and epigenome, for complex trait prediction. We apply our method to several human complex traits
and evaluate its performance. We show that combining mRNA and microRNA transcriptome data is
highly predictive of cellular growth, while using genetic variant data alone is not predictive. We show
that OmicKriging using genotype and expression data predicts a clinical statin response phenotype better
than the polygenic score method. In a study of seven common diseases from the Wellcome Trust Case
Control Consortium, we show performance of OmicKriging is similar to more computationally intensive
approaches.
Introduction
High-confidence prediction of complex traits is an ultimate goal of personalized medicine. For heritable
traits, genotypic similarity contributes to phenotypic similarity. While genome-wide association studies
(GWAS) have revealed many statistically significant loci associated with complex traits, the small effect
sizes of most loci limit their prediction utility [1]. For most complex traits, an appreciable proportion
of phenotypic variance is explained only when polygenic models, rather than single-marker tests, are
used [2, 3]. For example, 45% of the variance in human height can be explained using a mixed linear
modeling approach (GCTA) that simultaneously considers all 300K common SNPs genotyped [3, 4].
Because this approach does not rely on selection of loci, it is thought to be appropriate for traits with a
3highly polygenic or infinitesimal genetic architecture [5, 6].
In order to intuitively understand our approach to phenotype prediction from genomic data, an analogy
from the field of geostatistics is useful. Kriging interpolates the value of some geographical measurement
such as yearly rainfall at an unobserved location [7–9]. The approach assumes the rainfall measured at
nearby locations will be more similar to that at the unmeasured location than rainfall at sites farther away.
Kriging uses weights based on the correlation matrix of these locations along with the observed rainfall
amounts to predict the rainfall at the unmeasured location. The locations are analogous to individuals
and the rainfall amounts are analogous to the phenotype of interest (Figure 1). In our application to
complex trait prediction, the notion of distance can be replaced with the degree of genetic similarity or
dissimilarity. Close ties between genetic distance and geographic distance have been demonstrated in
studies of human population structure. For example, in the analysis of genome-wide genotype data from
3000 Europeans, a geographic map of Europe arose naturally when the first two principal components of
the data were plotted [10]. A diagram of the analogy between geostatistical kriging and complex trait
prediction is shown in Figure 1.
Methods of complex trait prediction using whole-genome data were pioneered by Meuwissen et al. [11]
who proposed to predict the genetic effects on phenotypes as the sum of marker effects
∑
l=1Xilβˆl, where
Xil is the genotype of individual i for marker l and βˆl is the estimated effect size of marker l. One
early application to human disease risk used a polygenic score derived from the logistic regression effect
sizes of GWAS SNPs with P-values below a chosen threshold in a training set to predict a significant
proportion of the risk of schizophrenia and bipolar disorder in test sets [2]. The training set was a large
schizophrenia GWAS and the testing sets included multiple additional schizophrenia, as well as bipolar
disorder, datasets. A similar polygenic score approach was used to predict risk of the seven diseases
within the WTCCC, by dividing each sample into training sets and test sets [12]. When implementing
polygenic score for trait prediction, the single-marker association effect sizes of SNPs that meet a chosen
threshold from the training set are multiplied by the genotypes (0,1,2) of each respective SNP in the
test set and the sum taken to generate a predicted phenotype value (polygenic score) for each individual.
Performance of the polygenic score model is then assessed by comparing predicted to observed values.
Principal components or any other known covariates that associate with the phenotype can be included
in the polygenic score model to further improve prediction.
Additional whole-genome prediction (WGP) methods, which are reviewed in de los Campos et al. [1]
4and Abraham et al. [13], include penalized estimation methods such as Least Absolute Shrinkage and
Selection Operator (LASSO) [14], Ridge Regression [15], and Elastic Net [13,16] and the Bayesian versions
of each method [17, 18]. These methods use different penalty functions or different types of priors to
overcome the infeasibility of estimating marker effects through ordinary least squares regression in typical
GWAS datasets with much larger numbers of markers than individuals. These methods prevent over-
fitting and may reduce the mean-squared error of estimates and predictions [1]. As an example, Vazquez
et al. used Bayesian LASSO to structure the prior density of marker effects in their Bayesian regression
WGP model of skin cancer risk [19]. Their best prediction model, which included 41K genome-wide
SNPs, had an area under the receiver operating characteristic curve (AUC) of 0.635, 18.9% higher than
that of the baseline model, which just included non-genetic covariates [19].
The idea of using genetic similarity to generate prediction dates back to Fisher [20] and Wright [21].
These ideas were formalized as best linear unbiased prediction (BLUP) approaches based on multivariate
normal processes by Henderson, Goldberger and others [22–24]. Originally, these methods used pedigree
based similarity matrices but with the advent of affordable high throughput genotyping several authors
have used similarity measures computed using larger numbers of genetic markers [3,5,6,25–29]. These ap-
proaches are commonly called G-BLUP for genomic-BLUP. Unlike the polygenic score methods, G-BLUP
regresses phenotypes on hundreds of thousands of markers simultaneously using a genetic relationship
matrix (GRM) derived from the marker data. While most applications of G-BLUP have assumed all mea-
sured genotypes affect the phenotype with normally distributed effect sizes and thus include all markers
in the GRM, a newer approach by Zhou et al. combines G-BLUP with a sparse regression model that
allows for a small proportion of markers with large effect sizes and estimates the most likely model for a
particular phenotype from the data [30].
The equivalence between Kriging and the BLUP methods used in the animal breeding and quantitative
genetics fields has been demonstrated [31,32]. Ridge regression is equivalent to standard Kriging/BLUP,
but does not have the dimension reduction advantage that the latter offers. Kriging in genomic prediction
has been previously used, but it was restricted to simulation studies of genetic similarities [33]. Based on
whole genome simulations, Ober et al. reported that using Mate´rn functions (class of special functions
commonly used in geostatistics) to scale the genetic relatedness measure works better than standard
measures of relatedness in the presence of dominance and epistatic effects [33].
The main novelty of our approach is the extension of the Kriging framework for the integration of
5multiple omic data. Furthermore, this framework allows easy integration of prior information on the
function of the variants by partitioning the genome and giving more weight to different subsets based
on functional evidence. For example, known loci can be given more weight than the rest of the genome,
or subsets of the genome with regulatory evidence of affecting gene expression (eQTLs) can be given
larger weight. It differs from standard Kriging/BLUP in that it is not necessarily tied to an additive
genetic/genomic model. Instead of using the maximum likelihood method to estimate the parameters we
use a more pragmatic approach where we maximize the cross validated prediction performance. In this
sense, our approach is closely related to the semi-parametric models using reproducing kernel Hilbert
space (RKHS) regression proposed by Gianola et al. [34] and de los Campos et al. [35] for WGP. To our
knowledge, our method is the first to integrate multiple omics data using these semi-parametric methods
based on similarity measures. Furthermore, our intuitive connection between Kriging and BLUP should
allow investigators less familiar with the quantitative genetics field to appreciate the usefulness of the
approach and encourage them to adopt these methods for their specific analyses.
In sum, we propose a novel systems approach to predict complex traits, which leverages and inte-
grates similarity in genetic, transcriptomic, and/or other large scale omics data. Here, we describe our
OmicKriging method, apply the method to several human complex traits (cellular growth, clinical statin
response and seven WTCCC diseases), and provide an R package for implementation.
Results
In implementing OmicKriging, the first step is to construct a similarity matrix or similarity matrices for
use in the prediction. Such matrices may include a genetic relationship matrix (GRM) from a set of SNPs,
a gene expression correlation matrix (GXM) from gene expression data, or any other correlation matrix
derived from omics data. To predict the phenotype of an individual, the weighted average of the training
set individuals’ phenotypes is calculated. In the case of SNP data, the weights are comprised of the GRM
and pairwise genotype similarity of the unknown individual with the genotypes of those with observed
phenotypes. Each similarity matrix can be tested individually or in a given weighted combination for
phenotype predictive performance. When using a single omic component, we tested weights between 0
and 1 (i.e. 0.1, 0.2, 0.3, ..., 1 for the omic component and 1-weight for the environmental component) to
find the weight that produced optimal prediction. When two omic components (e.g. GRM and GXM)
6were combined, we performed a grid search to find the optimal prediction weights w1 and w2, such that
w1 +w2 ≤ 1 (1-w1-w2 for the environmental component). The optimal weights for each omic component
depend on the genetic architecture of the phenotype.
In applying OmicKriging, we used a 16-fold cross-validation approach with individuals assigned to
the 16 subsets at random and repeating the procedure 500 time to assess the sampling variability of
the prediction performance (see Methods). For quantitative traits, we computed the coefficient of deter-
mination R2 (equivalent to the square of the correlation) between the predicted and true values of the
phenotype to assess prediction performance and for case/control traits, we computed the area under the
receiver operating characteristic curve (AUC). Note that in the OmicKriging method, weighted averages
are computed out-of-sample (only an individual’s genotypes or gene expression levels are used to compute
pairwise similarities) and should not be compared to reports where the R2 is computed using parameters
estimated from the same data (in-sample).
Cellular phenotype applications
To assess the predictive performance of OmicKriging, we used the intrinsic growth rate (iGrowth) pheno-
type derived from multiple proliferation measurements in the commonly used HapMap lymphoblastoid
cell lines (LCLs) [36]. This phenotype is relevant since it has been shown that genes associated with
proliferation are strong prognostic factors in several types of cancers [37–40] and such genes are differen-
tially expressed in most cancer tissues [41–43]. In addition, our unpublished data indicate that predicted
drug-induced growth inhibition has predictive power on clinical response to drugs. iGrowth values from
99 LCLs from the HapMap CEU (Northern and Western European ancestry from Utah) and YRI (Yoruba
from Ibadan, Nigeria) populations were used in the analysis. We tested common SNPs, gene (mRNA)
expression levels, and microRNA expression levels for iGrowth predictive ability. The GRM was gener-
ated from 2.7 million common SNPs (minor allele frequency > 0.05) from HapMap [44] using GCTA [4]
embedded in our OmicKriging R package. The GXM was generated from 13,080 transcript clusters from
a previous genome-wide gene expression analysis [45] as simply the correlation matrix of the expression
data as described in the Methods. We also obtained expression measurements for 201 microRNAs [46]
and generated a microRNA expression similarity matrix (MXM).
We first tested each single similarity matrix for predictive ability using OmicKriging. At every weight
wGRM attempted (wGRM = 0.1, 0.2, ..., 1 and w = 1−wGRM), the GRM did not show any predictive power
7(i.e. the correlation between the predicted and true iGrowth values did not differ from zero). However, for
the GXM alone, the optimal prediction correlation was R2 = 0.38 [0.34, 0.43] when wGXM = 1 (Figure2A).
The 95% confidence interval of each prediction [in brackets] was determined by 500 permutations of
randomly partitioning the data into training and test sets as described in the Methods. In addition,
for the MXM alone, the optimal prediction correlation was R2 = 0.35 [0.32, 0.38] when wMXM = 0.4
and w = 0.6 (Figure2B). We then performed a grid search to determine if combining the GXM and
MXM similarity matrices improved the iGrowth prediction. The optimal prediction from the grid search
increased the correlation to R2 = 0.48 [0.45, 0.52], when wGXM = 0.8, wMXM = 0.1, and w = 0.1
(Figure2C-D). The non-overlapping confidence intervals indicate that combining genome-wide expression
data improved the iGrowth predictive power of OmicKriging over using either the GXM or MXM alone.
We developed a baseline model similar to a polygenic score model, but with the top gene and mi-
croRNA expression associations rather than SNP associations, to compare to our OmicKriging results.
Specifically, using the entire sample, we determined that 255 genes and 14 microRNAs associated with
iGrowth by univariate linear regression after Bonferroni correction for multiple tests. Then, we performed
16-fold cross-validation by determining the top 255 genes and top 14 microRNAs by univariate linear
regression in each training set and using the effect sizes to predict iGrowth in each test set. In addition
to the top 255 genes and top 14 microRNAs from each training set, we also included the first 10 principal
components derived from the genotype data in each multivariate prediction model. We repeated the
cross-validation procedure 500 times to generate a confidence interval. The baseline model was unable
to predict iGrowth, R2 = 0.0038 [-0.010, 0.064]. Therefore the maximum R2 = 0.48 obtained by OmicK-
riging represents a vast improvement in iGrowth prediction over the baseline model of top expression
associations (Table 1).
Clinical phenotype applications
Clinical statin response We also applied OmicKriging to the Cholesterol and Pharmacogenetics
(CAP) Simvastatin Study, which contains both genome-wide genotype and expression data [47–49]. DNA
samples were either genotyped on the Illumina HumanHap 300K beadchip or the Illumina HumanHap
610K-Quad beadchip. A total of 562 individuals had their change in low-density lipoprotein cholesterol
(dLDLC) after simvastatin treatment measured and also passed genotyping quality control. Additional
SNP genotypes were imputed into these samples using data from the 1000 Genomes Project [50]. To assess
8potential predictive ability of the SNPs, we estimated the heritability of dLDLC captured by the 8.7M
imputed SNPs to be 0.69 (SE 0.61) using GCTA [4]. Because of the large standard error obtained when
all the SNPs were used, we sought to obtain a significant estimate of heritability by using a subset of SNPs
known to be involved in statin response from a separate study. The Heart Protection Study identified
45 SNPs (Tables 2 and S3 in Hopewell et al.) to be involved in LDLC response to simvastatin [51]. We
used SNPs within 50kb of these 45, for a total of 10,925 SNPs, and obtained a heritability estimate for
dLDLC of 0.16 (SE 0.079, P = 0.01). The estimated heritability is quite low but the fact that it is
significantly different from zero indicated that significant predictive power might be attainable. When
we applied OmicKriging to the CAP SNP data for dLDLC prediction, the optimal prediction correlation
was R2 = 0.037 [0.026, 0.049] when wGRM = 0.8 using a single GRM calculated from the Hopewell 50kb
SNPs. Adding a second GRM of all imputed SNPs and performing a grid search did not improve the
dLDLC prediction.
To compare our OmicKriging method to existing WGP methods, we used polygenic score and at-
tempted several sets of top SNPs for prediction of dLDLC using a 16-fold cross-validation approach. The
best prediction had R2 = 0.016 [0.0048, 0.030] when the top 1000 SNPs from each training set were used
to predict the respective test set, which is less than half the prediction R2 obtained with OmicKriging
(R2 = 0.037, Table 2).
Of the 562 individuals in the CAP study, 461 of them also had gene expression measurements from
LCLs derived from their blood. Patient LCLs were exposed to simvastatin or vehicle control (baseline)
for 24H and then gene expression was measured using the Illumina Ref8v3 beadchip [48]. The differences
between the treated and baseline expression values for each individual were used to generate a GXM.
Including all 12,951 expressed genes in the GXM and performing a grid search with the Hopewell GRM
did not improve the dLDLC prediction over the GRM alone. Like we did for the SNPs, we then chose to
only include genes from candidate pathways known to be involved in lipid metabolism and inflammation
in the GXM in an attempt to improve prediction. Combining a GXM of the 28 expressed genes from the
PID RHOA REG PATHWAY from the Molecular Signatures Database (MSigDB) [52] with a GRM of the
Hopewell SNPs produced an optimal R2 = 0.025 [0.014, 0.036] when wGXM = 0.3 and wGRM = 0.6. This
prediction was not significantly different from using the Hopewell GRM alone with this reduced sample
size (R2 = 0.024 [0.015, 0.035], when wGRM = 0.9). We also developed a baseline model using the 45
SNPs reported by Hopewell et al. combined with the first 10 principal components and the top 396 gene
9expression levels in a polygenic score prediction, but the R2 was negligible (R2 = −0.00014 [−0.0022,
0.0070]). Thus, combining the genotype and gene expression data did not improve the prediction (Table
2).
WTCCC diseases To test the predictive power of OmicKriging using larger clinical datasets, we
turned to the seven diseases of the Wellcome Trust Case Control Consortium (WTCCC) [53]. First, for
each case/control dataset, all genotyped common SNPs (approximately 400,000) were used to generate a
GRM. OmicKriging was run using these single GRMs (equivalent to G-BLUP) and case/control prediction
was successful (AUC > 0.50 which would be considered random guess) for all seven diseases as has been
shown previously [30]. In our analysis, mean areas under the ROC curve (AUCs) ranged from 0.598
[0.593, 0.604] when wGRM = 0.4 for coronary artery disease to 0.713 [0.709, 0.717] when wGRM = 0.4
for type 1 diabetes (Figure 3, Table 3). The 95% confidence intervals [in brackets] were determined
by randomly partitioning the data 500 times into 16 subsets and performing cross-validated prediction
on every random partition to generate a distribution of 500 AUC values. While we did perform a grid
search to determine the best AUC for each WTCCC disease, optimization typically resulted in minimal
improvement. That is, the optimized wGRM did not improve the AUC greater than 0.02 over the default
wGRM = 1.
In an attempt to further improve the prediction by integrating existing information on variants from
previous studies, we generated a second GRM for each disease using the SNPs within 100kb of known
loci (identified outside of WTCCC studies for each disease) listed in the The National Human Genome
Research Institute GWAS catalog [54] and the Database of Genotypes and Phenotypes (dbGAP) [55].
The optimal double GRM improved the predictive power of OmicKriging over using just the single
common-SNP GRM alone slightly for coronary artery disease and type 2 diabetes and dramatically for
Crohn’s disease, rheumatoid arthritis, and type 1 diabetes (Figure 3). The type 1 diabetes prediction
showed the largest improvement when the second GRM was added: the AUC increased from 0.713 to
0.891 [0.889, 0.892] (Figure 3, Table 3).
We compared OmicKriging to a baseline model that uses only genome-wide significant SNPs and the
first ten principal components to calculate predicted phenotypes by the polygenic score method. Both
OmicKriging models (single and double GRM) outperformed the baseline model for coronary artery
disease, hypertension, type 2 diabetes, and bipolar disorder (Figure 3, Table 3). The OmicKriging double
10
GRM model greatly outperforms the baseline model for Crohn’s disease, rheumatoid arthritis, and type 1
diabetes. The greatest differences between models were seen for rheumatoid arthritis and type 1 diabetes,
where the OmicKriging mean AUCs were 0.08 and 0.12 higher than the baseline polygenic score mean
AUCs, respectively (Figure 3, Table 3).
Discussion
We propose a novel systems approach to predict complex traits, which leverages and integrates similarity
in genetic, transcriptomic and/or other large scale omics data. We translate the genomic similarity
into phenotypic similarity using a method called Kriging, commonly used in geostatistics and machine
learning. Here, we construct the genomic similarity using a linear combination of omic similarity matrices
(in addition to the environmental component), but more general similarity matrices can be used. Given
the similarity matrix, the prediction is obtained by simply computing a weighted average of the phenotype
of individuals in the training set. The weights are provided by the Kriging method, which can be loosely
interpreted as a converse of the linear regression method. Our method is a fast, simple and flexible
approach to polygenic, and more generally poly-omic, prediction.
The key component of the method is the choice of the similarity matrix. If we assume certain
conditions such as additive poly-omic models (as described in the Methods section) it is possible to
estimate the weights for each omic component as well as the environmental component using a (restricted)
maximum likelihood approach or Bayesian generalizations. However, some of the modeling assumptions
are quite stringent and we opted for a more pragmatic approach in which we use the weights that maximize
predictive performance. In this manuscript, we use a grid search approach to find reasonably close to
optimal weights for each similarity matrix component (GRM of known large effect SNPs, GRM of all
SNPs, GXM, etc.).
Using mRNA (GXM) and microRNA (MXM) data in HapMap LCLs, we predict the cellular intrinsic
growth phenotype with an out of sample R2 of 0.48 with just 99 samples. For comparison, previous studies
using similar datasets had reported R2 values of the same magnitude but were computed in-sample, which
is known to be highly upward-biased. The combined mRNA-microRNA prediction R2 was 0.10-0.13
higher than using either the GXM or MXM alone. Given that 30% of gene expression levels associate
with the intrinsic growth phenotype (FDR<0.1) [36], it is perhaps not surprising that gene expression
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correlations are most useful in predicting this phenotype. However, using just the most significantly
associated expression levels as was done in the baseline polyscore model, was not predictive. These
results stress the importance of considering other potential biomarkers besides genotype, because the
GRM was not helpful in predicting this particular phenotype at this sample size. LCLs from populations
of both African and European descent were used in this analysis.
The issue of population stratification has slightly different implications in the prediction context than
it does in the GWAS estimation context. If our goal is to achieve the best prediction possible, we are
not concerned whether the predictive power comes from the genomic component or environmental and
populations stratification components that are confounded with the genomic component. Naturally, we
have to be aware of this limitation and not to expect similar levels of accuracy when predicting in different
population mixtures.
Because the dataset contained genotype and gene expression data, we used the CAP simvastatin study
to test the potential predictive ability of OmicKriging applied to a clinical phenotype with multiple types
of omics-level data. While the out-of-sample prediction correlations were not large with OmicKriging,
likely due to limited sample size, the best SNP-based prediction R2 was more than twice as high as that
obtained from the polygenic score method (R2 = 0.037 vs. R2 = 0.016). While inclusion of expression
data did not improve prediction over genetic variants alone, the CAP study examples demonstrate how
OmicKriging can be applied to multiple types and subsets of omics data for phenotypes with such data
available.
We also successfully predicted seven clinical disease risk phenotypes with OmicKriging. For WTCCC
disease prediction, we show that our OmicKriging method yields performance similar to or better than
polygenic score. In addition, OmicKriging when restricted to genotypic data performs just as well as
the computationally more intensive BSLMM method [30] (Table 3). The average OmicKriging double
GRM run time on a Xeon E5345 processor is 14 minutes, whereas the average GEMMA software [56]
run time for BSLMM is 28 hours on the Xeon L5420 processor, which is a slighly newer, but comparable
processor [30]. Most of the BSLMM run time is used for the Markov chain Monte Carlo (MCMC)
iterations, whereas in OmicKriging, we specify the sparse effects (known GWAS loci) before the run. For
the known autoimmune diseases (Crohn’s disease, rheumatoid arthritis, type 1 diabetes), adding a second
GRM of known loci increased the prediction AUC values over a single common SNP GRM alone to AUC
values slightly higher (not significant) than those obtained by BSLMM (Table 3). [30]. These autoimmune
12
diseases are known to have multiple associated loci of relatively strong effects, so this prior knowledge
was used to improve prediction performance [57]. Unless replicated in an independent study, the results
from the WTCCC data were not used to select top SNPs to avoid overfitting the data. The potential
for prediction improvement by differentially weighting markers based on trait specific information was
explored in simulated data by Zhang et al. using BLUP models [58].
While we recognize that assuming that a binary trait is continuous is not statistically optimal, we
do so here in our initial modeling for computational reasons, as have others [30, 59]. Linear probability
models for binary outcomes are considered to be adequate approximations when the proportion of cases
(and controls) exceed 25% given the approximate linearity of the logit or probit functions near the
origin [30]. It has been reported that the gain in statistical efficiency is hard to realize because of the
added computational burden and consequent loss in numerical accuracy [30, 60]. Unlike us, Vazquez et
al. used a probit link model for skin cancer incidence, but needed to restrict their analysis to only 41K
SNPs due to computer memory limitations [19]. In their dataset, the linear probability model would have
been less appropriate since the proportion of cases was between 11-24%.
While the equivalence between Kriging and BLUP methods used in the quantitative genetics field has
been demonstrated [31,32], our OmicKriging method differs from standard Kriging/BLUP in that we do
not prespecify a model. We use an additive poly-omic model to motivate the main functional form of
the similarity matrix but find the weights for each omic component (and the environmental component)
by maximizing the cross-validated prediction performance. Thus our approach is closely related to the
semi-parametric models using RKHS regression proposed by Gianola et al. [34] and the kernel averaging
approach proposed by de los Campos et al. [35] for WGP. We use an additive poly-omic model to motivate
the structure of the composite similarity matrix, but have ignored the cross-correlation terms between
different omic components by assuming independence of the effects from different sources. This is a very
restrictive assumption, but including the cross-correlation term is a complex topic that merits further
investigation. It may be possible to use eQTL information to restrict the number of non-zero correlations,
but even then further assumptions must be made to be able to estimate the needed parameters given
available data and computational limitations.
The main novelty we add to these Kriging/RKHS methods based on similarity measures is the inte-
gration of multiple types of large-scale omic data. Our OmicKriging framework allows easy integration
of prior information on the function of variants or pathways from heterogenous sources by giving more
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weight to different subsets of SNPs or gene expression levels without the sometimes heavy computational
burden of Bayesian approaches. For example, eQTLs could be given more weight than SNPs with no evi-
dence of regulatory function. In addition, expression levels in candidate pathways related to a particular
phenotype could be given more weight and tested for predictive performance. Furthermore, our analogy
comparing Kriging for rainfall to OmicKriging for phenotypic prediction and our applications to omic
data provide a more intuitive understanding of the method than a formal mathematical definition. This
should allow a broader audience to appreciate the usefulness of OmicKriging and to adopt the approach.
We provide an R package called OmicKriging and a tutorial explaining how to implement the kriging
algorithm at http://www.scandb.org/newinterface/tools/OmicKriging.html.
Methods
OmicKriging Approach
We propose to use an extension of the Kriging framework to integrate different omic data as well as prior
information on function such as existing GWAS studies, eQTL information (genetic markers associated
with gene expression levels), regulatory evidence such as provided by ENCODE studies, etc. We build the
similarity matrix as a linear combination of the similarity matrices from each omic component where the
coefficients or weights for each component are chosen so that prediction performance is maximized. Given
a similarity matrix, the usual Kriging formulas are used to compute the predicted values. Prediction is
performed by randomly partitioning the samples into 16 subsets and using each subset as the testing set
and the remaining 15 sets as the training set. This is repeated 500 times to assess the sampling variability.
The correlation squared between the true and predicted values are used as performance measures. For
binary/disease traits we use the area under the receiving operating curve. In this work, we assume a
linear probability model for the disease status following Lee et al. [59] and Zhou et al. [30].
Omic Similarity Matrix For each omic dataset used for prediction we compute the corresponding
similarity matrix. For convenience, we will denote the similarity matrix constructed from genetic data
as GRM, the one constructed by mRNA expression profile data as GXM, and the ones constructed with
microRNA expression data as MXM. We assume that the environmental component is independent across
individuals and is represented by the identity matrix, I. In the current implementation of the OmicKriging
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R package, we are computing the similarity matrix for genetic data by invoking the GCTA [4] software,
whereas for other omic data we compute the similarity matrix directly in R. More specifically, the ij
component of the GRM is computed as
1
M
M∑
l=1
(XGil − 2pl)(XGjl − 2pl)
2pl(1− pl)
and the ij component of the other omics data is computed as
L∑
l=1
(XOil − X¯Oi )(XOjl − X¯Oj )√∑
k(X
O
ik − X¯Oi )2
∑
k (X
O
jk − X¯Oj )2
where i and j denote individuals, XGil is the number of reference alleles of individual i at marker l, pl is
the reference allele frequency of marker l, XOil is the level of omic marker l (l is a dummy index and there
is no one to one correspondence between genetic and omic markers indices), M is the number of genetic
markers, L is the number of genes or omic markers, X¯Oi =
∑
kX
O
ik/L, and X¯
O
j =
∑
kX
O
jk/L.
By using the correlation without prior centering and standardizing the gene expression and other
continous omic traits, we are effectively giving more weight to the traits that have larger variance. The
effects of different choices of the similarity matrix on the prediction accuracy will be investigated in future
work.
Optimal similarity matrix under an additive model
A key component of the success of OmicKriging is understanding which proximity measures translate
best into phenotypic similarity. The optimal similarity matrix depends on the underlying genetic and
epigenetic architecture of the complex trait.
We will use an additive poly-omic model to motivate our choice of the similarity matrix. The pheno-
type for individual i, Yi (a scalar) is represented as
Yi = a+Gi + Ti +Oi + · · ·+ i
where
• a is a constant,
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• Gi =
∑M
l=1 β
G
l X
G
il is the additive genetic component (assumed to be known), β
G
l is the effect size
of the standardized genotype XGil , and M is the total number of genetic markers,
• Ti =
∑L
l=1 β
T
l X
T
il (assumed to be known), β
T
l is the effect size of the standardized gene expression
XTil and L is the total number of genes,
• Oi =
∑L′
l=1 β
O
l X
O
il is the additive (other) omic component (assumed to be known), β
O
l is the effect
size of the standardized omic level XOil , and L
′ is the total number of omic markers,
• and i is a noise term (iid, independent and identically distributed).
For notational convenience let us define Xi without a superscript to denote all three omic data such that
Xil = X
G
il if l ≤M , Xil = XTi,l−M if M < l ≤M +L and Xil = XOi,l−M−L if M +L < l ≤M +L+L′ and
similarly for coefficients β’s such that βl = β
G
l if l ≤M , βl = βTl−M if M < l ≤M + L and βl = βOl−M−L
if M + L < l ≤M + L+ L′.
We assume a random effects model for the β’s. For convenience we also assume that the X’s have
been centered and standardized. If we further assume that the betas are independent, i.e. that cov(β) =
σ2βI then the covariance matrix of the n-vector Y will have components
Σi,j = θG
M∑
l=1
XGilX
G
jl + θT
L∑
l=1
XTilX
T
jl + θO
L′∑
l=1
XOilX
O
jl + θδij (1)
where δij is the kronecker delta (1 if i = j and 0 otherwise) and θG, θT , and θO are non negative. If all
modeling assumptions were met and we assumed normality of the environmental term, this covariance
matrix should be used as the similarity matrix to compute the best linear unbiased prediction (BLUP).
However, these assumptions are quite strong and do not account for correlations of between marker
effects, gene-gene interactions, gene-environment interactions, etc. Thus, we adopt a pragmatic approach
in which we use a combination of the covariance matrices for each omic component but allow the weights
θ to vary and pick the combination that provides the best predictive performance.
Independence assumption for all betas is clearly too restrictive. The effect size of genetic marker XGil ,
βGl , that influences gene expression level X
T
ik is likely to be correlated with β
T
k . For unconstrained values
16
of the cov(βk,βl) the covariance matrix has the form
Σi,j = θG
M∑
l=1
XGikX
G
jk + θT
L∑
l=1
XTikX
T
jk + θO
L′∑
k=1
XOikX
O
jk + θδij
+
∑
k 6=l
cov(βk, βl)XikXjl
In case prior expression quantitative trait loci (eQTL, genetic markers that have an effect on gene expres-
sion traits) information is available, it may be possible to restrict the non zero cross-correlation terms to
known eQTL pairs (XGl ,X
T
k ). Additional restrictions in the values of the cov(βl, βk) must be imposed to
be able to characterize them given existing data and care must be taken to preserve positive definiteness
of Σ (all eigenvalues must be > 0). This is a complex topic that merits further research. In this paper,
to keep computations within reach, we ignore the cross-correlation terms and find the coefficient thetas
that maximize prediction performance.
Composite Similarity Matrix Based on the form of the optimal similarity matrix under an addi-
tive poly-omic model, we propose to use a composite similarity matrix that integrates different omic
components to be used for Kriging that is a linear combination of each component similarity matrix (Ss)
Σ = θ1S1 + θ2S2 + θ3S3 + · · ·+ (1− θ1 − θ2 − θ3 · · · )I
where the weights θ’s will be determined as the ones providing optimal prediction. All coefficients θ
are constrained to be non-negative. The environmental component is known as the nugget term in
geostatistical applications.
Kriging Formula
Within the kriging framework, the predicted phenotype of a test individual is computed as the weighted
average of the phenotype of the individuals in the training set.
Prediction(Ynew) = ω1Y1 + ω2Y2 + · · ·+ ωnYn (2)
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where the weights ωi are a function of all n(n + 1)/2 pairs of similarity measures. In the simplest case
where no covariates are needed, the weights prescribed by the Kriging method are given by
ω = Σ−1ρ (3)
where ρ is the similarity vector between the test individual and the training individuals and Σ is the
similarity matrix of the individuals in the training set [7]. Covariates are easily included in the method by
using the so called universal kriging approach [7]. Assuming there are p covariates (if only the intercept
is considered, p = 1), let z be the p by 1 vector with covariates 1 to p corresponding to the test individual
and Z be the n by p matrix with the p covariates for the n individuals in the training set. The weights
become
ω = Σ−1 (ρ+ Zm) (4)
where m = (Z′Σ−1Z)−1(z − Z′Σ−1ρ).
Prediction Performance
We measure prediction performance for binary traits with the area under the receiving operator char-
acteristic curve (AUC). For quantitative traits, we use R2, the correlation coefficient between true and
predicted values squared.
Grid Search
When using a single similarity matrix, we compared the prediction performance measures for similarity
matrix weights, w1 = 0, 0.1, 0.2, ...1, and environmental component weights, w = 1−w1. For two similar-
ity matrices (e.g. GRM and GXM) we allow matrix weights w1 = 0, 0.1, 0.2, ...1 and w2 = 0, 0.1, 0.2, ...1,
with the constraint that w1 +w2 ≤ 1. When two similarity matrices are used, the environmental compo-
nent weights are w = 1− w1 − w2.
Sampling Variability
To assess the uncertainty of the R2 or AUC estimates due to sampling variability, we randomly partitioned
each dataset 500 times into 16 subsets and performed cross-validation on every random partition. That
is, within each cross-validation fold, 1/16 of the data was used as the test set and 15/16 of the data was
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used as the training set. This random sampling and cross-validation generated a distribution of 500 R2
or AUC values for each prediction method and trait from which 95% confidence intervals were calculated
(as the 0.025 and 0.975 percentiles of the distribution of R2 or AUC values). All analyses were performed
using the R statistical language and environment [61].
Clinical statin response analysis
Genotype imputation Self-reporting Caucasian individuals from the Cholesterol and Pharmacoge-
netics Study [49] were genotyped on the Illumina HumanHap 300K beadchip (n=305) or the Illumina
HumanHap 610K-Quad beadchip (n=282). Prior to imputation, we performed standard GWAS quality
control, removing poorly called SNPs and SNPs in Hardy-Weinberg disequilibrium (HWD, P < 0.001).
We also removed related individuals and outliers for heterozygosity or principal components. This left
562 individuals, who also had baseline and post-simvastatin treatment LDLC measurements, for imputa-
tion. Prior to imputation we pre-phased the genotype data using SHAPEIT [62] using the recommended
settings. Then we used IMPUTE2 [63] to impute genotypes from the 1000 Genomes Project [50] using
the default settings for pre-phased data. A total of 8.7M SNPs with IMPUTE2-info scores > 0.3 and
minor allele frequency (MAF) > 0.001 and genotypes with probabilites > 0.9 were used in the heritability
estimation and prediction analyses.
Phenotype The change in low-density lipoprotein cholesterol (dLDLC) phenotype was calculated by
subtracting the log-transformed mean (over the two baseline measurements) of the baseline LDLC plasma
levels from the log-transformed mean (over the two visits post-treatment) of the LDLC plasma levels
collected while patients were on simvastatin [49].
Expression pathway analysis To test whether the gene expression of pathways potentially related
to simvastatin-induced LDLC response could predict dLDLC, we chose a few canonical pathways from
the MSigDB [52] to test in our OmicKriging model as proof-of-concept for future more comprehensive
pathway analyses. The pathways tested for prediction ability include BIOCARTA INFLAM PATHWAY,
PID RHOA PATHWAY, PID RHOA REG PATHWAY, and REACTOME CHOLESTEROL BIOSYN-
THESIS. While RHOA has been previously implicated in lipid metabolism and thus makes a plausible
candidate pathway, we focus on it here over many other potential lipid metabolism pathways, because
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recent functional work in the CAP LCLs have revealed specific effects of RHOA (ras homolog family
member A) in modulating the cholesterol-lowering effects of statin [48].
WTCCC disease analysis
We performed standard quality control for all WTCCC data sets. All WTCCC data sets were merged
into a single bed file where we removed all individuals recommended by the WTCCC. We removed SNPs
in HWD P < 0.0005 and MAF < 0.01. This resulted in approximately 388K SNPs after pruning. In
addition, we computed the GRM for all WTCCC and identified a pair of cases with unusually high
relatedness that were not included in the WTCCC removal list. The duplicate individual was removed.
OmicKriging models We selected SNPs from dbGAP and NHGRI to be used in the double GRM
model [54, 55]. We pruned all SNPs from studies that contained WTCCC datasets. We fit OmicKriging
models with single (all SNPs) and double GRMs (all SNPs and known GWAS SNPs) in 16-fold cross-
validation. This fold cross-validation number was chosen because OmicKriging can be multithreaded.
For these analyses, we used dual Xeon E5620 processors with 16 logical cores to run OmicKriging.
We performed a grid search (as described previously) to identify the optimal weights for single and
double GRM models (Table 3). Prediction performance of all OmicKriging and baseline models was
measured by area under the receiver operating characteristic (ROC) curve (AUC) with the package
ROCR in R [64]. We used the R package ggplot2 [65] to generate Figure 3.
Polygenic score models We applied the polygenic score method by fitting the first 10 principal compo-
nents and p genome-wide-significant loci jointly in 16-fold cross-validation (baseline model). Specifically,
we fit Y∼PC1 + · · · + PC10 + SNP1 + · · · + SNPp in each training set (15/16th of the dataset). With
the remaining test set (1/16th of the dataset), the m =p+10 estimated regression coefficients (βˆ) are
multiplied by an nxm matrix of n individuals and m principal components/genotype dosages (Zil) and
each individual’s predicted phenotype (polygenic score) is the sum of the respective individual’s products:∑m
l=1 Zilβˆl.
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Tables
Table 1. iGrowth prediction is maximized by integration of expression data through
OmicKriging.
Model: OmicKriging
GRM
OmicKriging
GXM
OmicKriging
MXM
OmicKriging
GXM+MXM
baseline
mean R2
[95% CI]
0.020 [-0.0083,
0.077]
0.38 [0.34,
0.43]
0.35 [0.32,
0.38]
0.48 [0.45,
0.52]
0.0038 [-0.010,
0.064]
matrix
weights
wGRM = 0.1,
w = 0.9
wGXM = 1,
w = 0
wMXM = 0.4,
w = 0.6
wGXM = 0.8,
wMXM = 0.1,
w = 0.1
NA
GRM = genetic relationship matrix, GXM = gene expression correlation matrix, MXM = microRNA
expression matrix, baseline = multivariate prediction model including top genes, top microRNAs, and
first ten principal components
Table 2. OmicKriging and other model performance for prediction of statin-induced
change in LDL cholesterol levels.
Model: OmicKriging
Hopewell
GRM
(n=562)
OmicKriging
Hopewell
GRM
(n=461)
OmicKriging
RHOA GXM
(n=461)
OmicKriging
Hopewell
GRM +
RHOA GXM
(n=461)
Polyscore
top1K
(n=562)
baseline
(n=461)
mean R2
[95% CI]
0.037 [0.026,
0.049]
0.024 [0.015,
0.035]
0.0021 [-
0.00086,
0.0057]
0.025 [0.014,
0.036]
0.016
[0.0048,
0.030]
-0.00014
[-0.0022,
0.0070]
matrix
weights
wGRM = 0.8,
w = 0.2
wGRM = 0.9,
w = 0.1
wGXM = 0.1,
w = 0.9
wGRM = 0.6,
wGXM = 0.3,
w = 0.1
NA NA
Hopewell GRM = genetic relationship matrix of Hopewell et al. [51] 50kb SNPs, RHOA GXM = gene
expression correlation matrix of RHOA regulatory pathway, Polyscore top1K = polygenic score model
of top 1K SNPs, baseline = multivariate prediction model including top genes, the 45 Hopewell et al.
SNPs, and first ten principal components
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Table 3. OmicKriging and other model performance for prediction of disease risk in the
WTCCC.
Disease Results OmicKriging
Single GRM
OmicKriging
Double GRM
BSLMM
(SD)*
baseline
BD mean AUC
[95% CI]
0.666 [0.661,
0.670]
0.665 [0.660,
0.670]
0.65 (0.02) 0.594
[0.590,0.597]
matrix
weights
wGRM = 0.3,
w = 0.7
wGRM = 0.4,
wGRMk = 0,
w = 0.6
NA NA
CAD mean AUC
[95% CI]
0.598 [0.593,
0.604]
0.610 [0.605,
0.616]
0.60 (0.03) 0.575 [0.572,
0.578]
matrix
weights
wGRM = 0.4,
w = 0.6
wGRM = 0.6,
wGRMk = 0.1,
w = 0.3
NA NA
CD mean AUC
[95% CI]
0.641 [0.636,
0.646]
0.707 [0.704,
0.710]
0.68 (0.02) 0.669 [0.667,
0.670]
matrix
weights
wGRM = 0.3,
w = 0.7
wGRM = 0.4,
wGRMk = 0.1,
w = 0.5
NA NA
HT mean AUC
[95% CI]
0.611 [0.606,
0.616]
0.611 [0.605,
0.616]
0.60 (0.02) 0.493 [0.485,
0.499]
matrix
weights
wGRM = 0.3,
w = 0.7
wGRM = 0.3,
wGRMk = 0,
w = 0.7
NA NA
RA mean AUC
[95% CI]
0.649
[0.644,0.654]
0.747 [0.744,
0.751]
0.72 (0.01) 0.668 [0.666,
0.669]
matrix
weights
wGRM = 0.2,
w = 0.8
wGRM = 0.2,
wGRMk = 0.5,
w = 0.3
NA NA
T1D mean AUC
[95% CI]
0.713 [0.709,
0.717]
0.891 [0.889,
0.892]
0.88 (0.01) 0.772 [0.770,
0.773]
matrix
weights
wGRM = 0.4,
w = 0.6
wGRM = 0.3,
wGRMk = 0.4,
w = 0.3
NA NA
T2D mean AUC
[95% CI]
0.618 [0.613,
0.624]
0.634 [0.630,
0.639]
0.61 (0.03) 0.609 [0.607,
0.611]
matrix
weights
wGRM = 0.3,
w = 0.7
wGRM = 0.7,
wGRMk = 0.1,
w = 0.2
NA NA
*values reported in Zhou et al. [30], BSLMM = Bayesian sparse linear mixed model, SD = standard
deviation, baseline = polygenic score model of known GWAS SNPs and first ten principal components,
AUC = area under the receiver operating characteristic curve, CI = confidence interval, GRM = genetic
relationship matrix (all SNPs), GRMk = genetic relationship matrix of known GWAS SNPs,
BD=bipolar disorder, CAD=coronary artery disease, CD=Crohn’s disease, HT=hypertension,
RA=rheumatoid arthritis, T1D=type 1 diabetes, T2D=type 2 diabetes
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Figure 1. Kriging and whole-genome prediction connection. This figure shows the analogous
relationships between components of the kriging method used in geostatistics and whole-genome
prediction. The prediction at an unobserved location (?) is computed as a weighted average of the
variable at observed locations. The weights are functions of the correlation between the rainfall at the
new location and the rainfalls at the observed locations. The closer the distance between each observed
location and the new location, the higher the weight. In complex trait prediction, locations correspond
to individuals, physical proximity corresponds to genetic relatedness. The correlation between two
locations or individuals is the key component of this method. In animal breeding approaches, the
genetic relatedness matrix or kinship matrix is used. In OmicKriging, a genetic relatedness matrix, a
gene expression similarity matrix, or any combination of available high-throughput data similarity
measures can be tested for complex trait prediction performance.
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Figure 2. iGrowth prediction using OmicKriging. Predicted versus true iGrowth (n=99) using
(A) the optimally weighted gene expression matrix (GXM) alone, (B) the optimally weighted
microRNA expression matrix (MXM) alone, and (C) the optimally weighted combination of the two
matrices from the grid search. The solid black lines represent the slopes of the regression between the
predicted and true values. The red dashed lines are the identity lines representing perfect prediction
(slope 1, intercept 0). (D) Results of the grid search which shows that the best iGrowth prediction
correlation (R2 = 0.48 [0.45, 0.52]) was obtained with (MXM, GXM) matrix weights of (0.1, 0.8). The
R2 values presented in the contour plot are the mean values from 500 random samplings of the data
into 16 cross-validation folds.
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Figure 3. OmicKriging prediction performance for WTCCC disease risk prediction.
Boxplots of the area under the ROC curve (AUC) from 500 permutations of the data for two
implementations of OmicKriging for each disease from the WTCCC: a single common SNP genetic
relationship matrix (OK:SingleGRM) and two optimally weighted GRMs of common SNPs and known
loci (OK:DoubleGRM) for the predictions. The double GRM AUCs dramatically increase for CD, RA,
and T1D, which are known to have multiple associated loci of relatively large effect. The known loci
were obtained from studies that did not include the WTCCC data to avoid over-fitting. For
comparison, we also show AUC results from 500 permutations of the polygenic score method using
genome-wide significant loci with 10 principal components (Baseline). Both OmicKriging
implementations outperform the baseline model for HT, CAD, T2D, and BD. The OK:DoubleGRM
greatly outperforms the baseline model for CD, RA, and T1D. BD=bipolar disorder, CAD=coronary
artery disease, CD=Crohn’s disease, HT=hypertension, RA=rheumatoid arthritis, T1D=type 1
diabetes, T2D=type 2 diabetes.
